Table 8.5.8 Duration of Lu-PSMA-617 administration by methods of administration (FAS Safety Set)

	PSMA-617-01 FDA Lab Table 8.5.8 Dura	tion of Lu-PSMA-617 administration by methods of	
<	Method of administrati	on	Lu-PSMA-617+BSC/BSoC (N=529)
C/i;	Overall	utes)	
	Signali	Duration of administration (minuni	2344
	21 0	Mean	10.6
	1/2; 16,		11.52
6 7,	Dx Jx	Median	5.0
70 40	(O) ()	Min Moy	0-101
00.00	· 10 (2)	Min-Max	0-101
5%	Gravity Method	SD Median Min-Max Gravity Method Duration of administration (minutes)	
(C)	dr Op	n `	228
\Q_{\text{O}}		Mean	28.5
	クメータカン	SD	9.49
	S. 16	Median	30.0
Ponsoi Suc	C/; C2	Min-Max	1-75
	1-75 Syringe with or without Pump Duration of administration (minutes) 228 Mean 28.5 SD 9.49 Median 30.0 Min-Max 1-75 Syringe with or without Pump Duration of administration (minutes) 228 Mean 28.5 SD 9.49 Median 30.0 Min-Max 1-75 Syringe with or without Pump Duration of administration (minutes) 228 Mean 28.5 SD 9.49 Median 30.0 Min-Max 1-75 Mean 1		
	100 0	· C/ · Nn	, 1773
		Mean	6.3
	· C2	O' SD S	8.10
	400	Median	2.0
	Q.	Min-Max	0-60
	Syringe with or without Pump Duration of administration (minutes) n Mean SD Median Min-Max Vial with Pump Duration of administration (minutes) n Mean SD Median SD Median Min-Max		utes)
	•	C > \(\sigma \) \	343
		Mean	21.2
		SD	0.00
		Median Min-Max	17.0
		Min-Max	2-101

n: Number of administrations with a start and end time.

Output ID: FDALBL-T-8-5-8 2021-11-30 16:20

Ct sous reserve des conditions d'antilisation G:\APPDATA\SAS_BIOMETRY\PROD\PROJECTS\PSMA617\VISION\FDA_REQUESTS\FDA_REQUEST_01

[\]PRODUCTION\TLF\PGM\t-admdur.sas

Data Cutoff Date: 27JAN2021